| Leitlinien für Diagnostik und Therapie in der Neurologie HC Diener, C Weimar, P Berlit, G Deuschl, C Elger, R Gold, W Hacke, ... Thieme Verlag, 2012 | 536 | 2012 |
| Vulnerability of the nigrostriatal system as detected by transcranial ultrasound D Berg, G Becker, B Zeiler, O Tucha, E Hofmann, M Preier, P Benz, W Jost, ... Neurology 53 (5), 1026-1026, 1999 | 462 | 1999 |
| Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications A Storch, CB Schneider, M Wolz, Y Stürwald, A Nebe, P Odin, A Mahler, ... Neurology 80 (9), 800-809, 2013 | 428 | 2013 |
| A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia R Benecke, WH Jost, P Kanovsky, E Ruzicka, G Comes, S Grafe Neurology 64 (11), 1949-1951, 2005 | 353 | 2005 |
| One hundred cases of anal fissure treated with botulin toxin: early and long-term results WH Jost Diseases of the colon & rectum 40 (9), 1029-1032, 1997 | 329 | 1997 |
| Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm P Roggenkämper, WH Jost, K Bihari, G Comes, S Grafe, ... Journal of neural transmission 113, 303-312, 2006 | 319 | 2006 |
| Gastrointestinal dysfunction in Parkinson's Disease WH Jost Journal of the neurological sciences 289 (1-2), 69-73, 2010 | 296 | 2010 |
| Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease A Storch, WH Jost, P Vieregge, J Spiegel, W Greulich, J Durner, T Müller, ... Archives of neurology 64 (7), 938-944, 2007 | 283 | 2007 |
| Gastrointestinal motility problems in patients with Parkinson’s disease: effects of antiparkinsonian treatment and guidelines for management WH Jost Drugs & aging 10, 249-258, 1997 | 241 | 1997 |
| High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study M Graf, D Ecker, R Horowski, B Kramer, P Riederer, M Gerlach, C Hager, ... Journal of neural transmission 112, 649-660, 2005 | 234 | 2005 |
| Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial AHV Schapira, SH Fox, RA Hauser, J Jankovic, WH Jost, C Kenney, ... JAMA neurology 74 (2), 216-224, 2017 | 231 | 2017 |
| Therapy of anal fissure using botulin toxin WH Jost, K Schimrigk Diseases of the colon & rectum 37, 1321-1324, 1994 | 195 | 1994 |
| Striatal FP-CIT uptake differs in the subtypes of early Parkinson’s disease J Spiegel, D Hellwig, S Samnick, W Jost, MO Möllers, K Fassbender, ... Journal of neural transmission 114, 331-335, 2007 | 192 | 2007 |
| Use of botulinum toxin in anal fissure WH Jost, K Schimrigk Diseases of the Colon & Rectum 36 (10), 974, 1993 | 191 | 1993 |
| Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease J Spiegel, D Hellwig, MO Möllers, S Behnke, W Jost, K Fassbender, ... Brain 129 (5), 1188-1193, 2006 | 180 | 2006 |
| Handbook of botulinum toxin treatment P Moore, M Naumann Wiley-Blackwell, 2003 | 179 | 2003 |
| Botulinum neurotoxin type A free of complexing proteins (XEOMIN®) in focal dystonia WH Jost, J Blümel, S Grafe Drugs 67, 669-683, 2007 | 176 | 2007 |
| Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm WH Jost, A Kohl Journal of neurology 248, I21-I24, 2001 | 176 | 2001 |
| Botulinum toxin: clinical use DD Truong, WH Jost Parkinsonism & related disorders 12 (6), 331-355, 2006 | 158 | 2006 |
| Autonomic dysfunctions in idiopathic Parkinson's disease WH Jost Journal of neurology 250, i28-i30, 2003 | 156 | 2003 |
A EsquenaziProfessor of Physical Medicine & RehabilitationAdresse e-mail validée de jefferson.edu
